Inactive Ingredients
Inactive Ingredients - Related Videos
10:25
Construction of Models for Nondestructive Prediction of Ingredient Contents in Blueberries by Near-infrared Spectroscopy Based on HPLC Measurements
0 Views •
Cited by 1 •
2016
We present here a protocol to construct and validate models for nondestructive prediction of total sugar, total organic acid, and total anthocyanin content in individual blueberries by near-infrared spectroscopy.
11:15
Pooled shRNA Screen for Reactivation of MeCP2 on the Inactive X Chromosome
0 Views •
Cited by 2 •
2018
We report a small hairpin RNA (shRNA) and next generation sequencing-based protocol for identifying regulators of X-chromosome inactivation in a murine cell line with firefly luciferase and hygromycin resistance genes fused to the methyl CpG binding protein 2 (MeCP2) gene on the inactive X chromosome.
05:03
Precise Electrochemical Sizing of Individual Electro-Inactive Particles
0 Views •
Cited by 1 •
2023
As an analytical technique, nanoimpact electrochemistry, an increasingly important approach to counting and characterizing nanometer-scale, electro-inactive particles, suffers from poor precision due to the heterogeneous current distributions that arise from its use of ultramicroelectrodes. Outlined here is a generalized approach, termed "electrocatalytic interruption," that enhances precision in such measurements.
04:37
Comprehensive Understanding of Inactivity-Induced Gait Alteration in Rodents
0 Views •
2022
The present protocol describes three-dimensional motion tracking/evaluation to depict gait motion alteration of rats after exposure to a simulated disuse environment.
08:27
A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome
0 Views •
2019
Here, we describe a protocol to generate a viable female murine model with non-random X chromosome inactivation, i.e., the maternally-inherited X chromosome is inactive in 100% of the cells. We also describe a protocol to test feasibility, tolerability, and safety of pharmacological reactivation of the inactive X chromosome in vivo.
FAQs
Inactive ingredients can help maintain a uniform formulation by supporting the active ingredient’s distribution, stability, and delivery. Binders and fillers contribute to the physical structure, while solvents or other formulation components help maintain an appropriate preparation. These functions matter because variation in the finished form could affect usability, dissolution, or consistent delivery of the medication.
Their effects depend partly on the dosage form. A tablet may require components that support disintegration, whereas liquid preparations depend on ingredients that help preserve stability. Topical products rely on suitable formulation components for application. Consequently, the same active ingredient can be experienced differently when delivered in tablet, liquid, or topical form.
Inactive ingredient profiles may differ among generic, brand-name, and alternative dosage forms while supporting the same active ingredient. These differences can affect a product’s color, taste, physical form, dissolution behavior, or usability. Comparing formulations is therefore relevant when a patient has a known allergy or intolerance or when acceptability influences medication selection.
Clinicians should review the formulation’s inactive ingredients when a patient has a known allergy or intolerance. They should also consider whether the dosage form is acceptable and appropriate for the intended use, since ingredients influence tablet disintegration, liquid stability, topical application, and other practical characteristics. This review can guide selection among available formulations.
Alternative dosage forms become particularly relevant when patient acceptability or the characteristics of administration matter. Tablets, liquids, and topical preparations may differ in how they are used, maintained, or experienced because their supporting ingredients serve different formulation needs. Considering these differences helps clinicians evaluate options beyond the active ingredient alone when selecting a medication.
During formulation development, teams evaluate how inactive ingredients support uniformity, stability, dissolution, disintegration, and practical use. Quality control then helps assess whether the finished medication maintains these intended characteristics. This process is important for tablets, liquids, and topical products because each dosage form depends on appropriate formulation behavior for consistent preparation and use.